首页> 美国卫生研究院文献>European Journal of Hospital Pharmacy >2SPD-007 Comparative effectiveness and safety of everolimus and axitinib as second-line therapy in metastatic renal cell carcinoma

【2h】

2SPD-007 Comparative effectiveness and safety of everolimus and axitinib as second-line therapy in metastatic renal cell carcinoma

机译：everolimus和Axitinib的2SPD-007对比较效果和安全性肾细胞癌中的二线治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Both everolimus and axitinib are approved for patients with metastatic renal cell carcinoma (mRCC) in second-line therapy. Currently, there are no comparative clinical trials reported.

机译：在二线治疗中批准艾弗莫斯和Axitinib均批准用于转移性肾细胞癌（MRCC）。目前，没有报告比较临床试验。

著录项

期刊名称 European Journal of Hospital Pharmacy
作者
R Collado-Borrell; V Escudero-Vilaplana; C Ortega-Navarro; E García-Martín; A Herranz-Alonso; M Sanjurjo-Saez;
展开▼
作者单位

展开▼
年(卷),期 2018(25),Suppl 1
年度 2018
页码 A12–A13
总页数 2
原文格式 PDF
正文语种
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review [J] . Vogelzang Nicholas J., Pal Sumanta K., Signorovitch James E., Current medical research and opinion . 2016,第4期

机译：依维莫司和阿昔替尼作为美国转移性肾细胞癌的第二种靶向治疗方法的比较有效性：回顾性图表回顾
2. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma [J] . Lajos Gczi, Gyrgy Bodoky, Gyrgy Rokszin, Pathology oncology research: POR . 2020,第4期

机译：二线Axitinib与everolimus在转移肾细胞癌中的第一线Sunitinib治疗后生存益处
3. COST-EFFECTIVENESS ANALYSIS OF USING EVEROLIMUS OR AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE FAILED TO USE OF PAZOPANIB OR SUNITINIB IN FIRST-LINE TREATMENT [J] . Romero Prada M. E., Huerfano L. M., Roa Cardenas N. C. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：在已经成功使用帕唑帕尼或舒尼替尼治疗一线治疗的转移性肾细胞癌患者中使用依维莫司或阿昔替尼的成本效益分析
4. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
5. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
6. Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study [O] . Yoshifumi Kadono, Hiroyuki Konaka, Kouji Izumi, 2019

机译：细胞因子与一线舒尼替尼和二线阿昔替尼治疗转移性肾细胞癌的疗效和安全性（ESCAPE研究）：III期随机顺序开放标签研究的研究方案
7. PCN60 Cost of Care with Everolimus Versus Axitinib for Second-Line Metastatic Renal Cell Carcinoma Patients in Canada [O] . Perrin A., Chua A., Wang X., 2013

机译：在加拿大，二线转移性肾细胞癌患者使用依维莫司和阿昔替尼治疗的PCN60费用

2SPD-007 Comparative effectiveness and safety of everolimus and axitinib as second-line therapy in metastatic renal cell carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅